ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients With Locally Advanced or Metastatic Cancers
immuneACCESS
◽
10.21417/ad2021ccr
◽
2021
◽
Author(s):
A Diab
◽
O Hamid
◽
JA Thompson
◽
W Ros
◽
FALM Eskens
◽
...
Keyword(s):
Phase I
◽
Dose Escalation
◽
Locally Advanced
◽
Open Label
◽
Dose Escalation Study
◽
Label Dose
Download Full-text
Related Documents
Cited By
References
A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status
Cancer Medicine
◽
10.1002/cam4.1140
◽
2017
◽
Vol 6
(8)
◽
pp. 1904-1914
◽
Cited By ~ 11
Author(s):
Benjamin Izar
◽
William Sharfman
◽
F. Stephen Hodi
◽
Donald Lawrence
◽
Keith T. Flaherty
◽
...
Keyword(s):
Phase I
◽
Metastatic Melanoma
◽
Dose Escalation
◽
Braf Mutation
◽
Locally Advanced
◽
Open Label
◽
Dose Escalation Study
◽
Mutation Status
◽
Label Dose
Download Full-text
414 POSTER A phase I, open-label, dose escalation study of the humanized monoclonal antibody (HuMAb) TRC093, an inhibitor of angiogenesis that binds to cleaved collagen, in patients with locally advanced or metastatic solid tumors
European Journal of Cancer Supplements
◽
10.1016/s1359-6349(08)72348-6
◽
2008
◽
Vol 6
(12)
◽
pp. 130
◽
Cited By ~ 1
Author(s):
M.S. Gordon
◽
L.S. Rosen
◽
F. Robert
◽
D.S. Mendelson
◽
D. Kleinzweig
◽
...
Keyword(s):
Monoclonal Antibody
◽
Phase I
◽
Solid Tumors
◽
Dose Escalation
◽
Locally Advanced
◽
Open Label
◽
Dose Escalation Study
◽
Humanized Monoclonal Antibody
◽
Label Dose
Download Full-text
A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients With Locally Advanced or Metastatic Cancers
Clinical Cancer Research
◽
10.1158/1078-0432.ccr-21-0845
◽
2021
◽
pp. clincanres.0845.2021
Author(s):
Adi Diab
◽
Omid Hamid
◽
John A Thompson
◽
Willeke Ros
◽
Ferry A.L.M. Eskens
◽
...
Keyword(s):
Phase I
◽
Dose Escalation
◽
Locally Advanced
◽
Open Label
◽
Dose Escalation Study
◽
Label Dose
Download Full-text
411 POSTER A phase I, open-label, dose-escalation study of the safety and pharmacology of MetMAb, a monovalent antagonist antibody to the receptor c-Met, administered IV in patients with locally advanced or metastatic solid tumors
European Journal of Cancer Supplements
◽
10.1016/s1359-6349(08)72345-0
◽
2008
◽
Vol 6
(12)
◽
pp. 129
◽
Cited By ~ 11
Author(s):
R. Salgia
◽
A. Peterson
◽
S. Eppler
◽
W. Yu
◽
B. Polite
◽
...
Keyword(s):
Phase I
◽
Solid Tumors
◽
Dose Escalation
◽
Locally Advanced
◽
Open Label
◽
Dose Escalation Study
◽
Label Dose
Download Full-text
Abstract 1752: A phase I/IIa, first time in human, open-label dose-escalation study of GSK2636771 in subjects with advanced solid tumors with PTEN deficiency
10.1158/1538-7445.am2012-1752
◽
2012
◽
Cited By ~ 4
Author(s):
Samuel C. Blackman
◽
Shelby D. Gainer
◽
Benjamin B. Suttle
◽
Konstantine W. Skordos
◽
Joel D. Greshock
◽
...
Keyword(s):
Phase I
◽
Solid Tumors
◽
Dose Escalation
◽
Advanced Solid Tumors
◽
Open Label
◽
Dose Escalation Study
◽
Label Dose
◽
First Time
Download Full-text
A phase I, open-label, multi-center, dose-escalation study of codrituzumab, an anti-glypican-3 monoclonal antibody, in combination with atezolizumab in patients with locally advanced or metastatic hepatocellular carcinoma
Annals of Oncology
◽
10.1093/annonc/mdy282.080
◽
2018
◽
Vol 29
◽
pp. viii234-viii235
◽
Cited By ~ 1
Author(s):
A.-L. Cheng
◽
C.-J. Yen
◽
T. Okusaka
◽
M. Ikeda
◽
C.-H. Hsu
◽
...
Keyword(s):
Hepatocellular Carcinoma
◽
Monoclonal Antibody
◽
Phase I
◽
Dose Escalation
◽
Locally Advanced
◽
Open Label
◽
Dose Escalation Study
◽
Metastatic Hepatocellular Carcinoma
Download Full-text
Combination of CpG7909 and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL): A phase I, open label dose-escalation study of safety and tolerability
Journal of Clinical Oncology
◽
10.1200/jco.2004.22.90140.6594
◽
2004
◽
Vol 22
(14_suppl)
◽
pp. 6594-6594
Author(s):
G. J. Weiner
◽
B. K. Link
◽
J. Leonard
◽
C. Emmanouilides
◽
G. Albert
◽
...
Keyword(s):
Phase I
◽
B Cell
◽
Dose Escalation
◽
Hodgkin’S Lymphoma
◽
Hodgkin's Lymphoma
◽
Open Label
◽
Dose Escalation Study
◽
Non Hodgkin’S Lymphoma
◽
Non Hodgkin's Lymphoma
◽
Label Dose
Download Full-text
Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid tumors.
Journal of Clinical Oncology
◽
10.1200/jco.2011.29.15_suppl.3033
◽
2011
◽
Vol 29
(15_suppl)
◽
pp. 3033-3033
◽
Cited By ~ 19
Author(s):
A. L. Ho
◽
J. C. Bendell
◽
J. M. Cleary
◽
G. K. Schwartz
◽
H. A. Burris
◽
...
Keyword(s):
Phase I
◽
Solid Tumors
◽
Dose Escalation
◽
Advanced Solid Tumors
◽
Open Label
◽
Dose Escalation Study
◽
Label Dose
Download Full-text
Abstract CT038: A phase I, open-label, dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of GSK3326595 in subjects with solid tumors and non-Hodgkin's lymphoma
10.1158/1538-7445.am2017-ct038
◽
2017
◽
Cited By ~ 2
Author(s):
Drew Rasco
◽
Anthony Tolcher
◽
Lillian L. Siu
◽
Kimberley Heinhuis
◽
Sophie Postel-Vinay
◽
...
Keyword(s):
Phase I
◽
Solid Tumors
◽
Dose Escalation
◽
Hodgkin’S Lymphoma
◽
Hodgkin's Lymphoma
◽
Clinical Activity
◽
Open Label
◽
Dose Escalation Study
◽
Non Hodgkin's Lymphoma
◽
Label Dose
Download Full-text
A Phase I, first-in-human, open label, dose escalation study of MGD007, a humanized gpA33 × CD3 dual-affinity re-targeting (DART®) protein in patients with relapsed/refractory metastatic colorectal carcinoma
Journal for ImmunoTherapy of Cancer
◽
10.1186/2051-1426-2-s3-p86
◽
2014
◽
Vol 2
(Suppl 3)
◽
pp. P86
◽
Cited By ~ 7
Author(s):
Herbert Hurwitz
◽
Todd Crocenzi
◽
Joanna Lohr
◽
Ezio Bonvini
◽
Syd Johnson
◽
...
Keyword(s):
Colorectal Carcinoma
◽
Phase I
◽
Dose Escalation
◽
Metastatic Colorectal Carcinoma
◽
Open Label
◽
Dose Escalation Study
◽
Label Dose
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close